FMP
Inozyme Pharma, Inc.
INZY
NASDAQ
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
2.99 USD
0.18 (6.02%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Douglas A. Treco Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.inozyme.comexchange
NASDAQ
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
CIK
0001693011
ISIN
US45790W1080
CUSIP
45790W108
Address
321 Summer Street
Phone
857 330 4340
Country
US
Employee
59
IPO Date
Jul 24, 2020
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
INZY Financial Summary
CIK
0001693011
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
45790W108
ISIN
US45790W1080
Country
US
Price
2.99
Beta
1.54
Volume Avg.
466.99k
Market Cap
192.08M
Shares
-
52-Week
2.385-7.795
DCF
-0.23
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.93
P/B
-
Website
https://www.inozyme.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest INZY News
It looks like there's no news available.
